Pernix Therapeutics (NASDAQ: PTX) is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and psychiatry, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its Pernix sales force, uses contracted sales organizations to market its non-core, cough and cold products, and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceutical, LLC and Cypress Pharmaceuticals, Inc. Pernix Therapeutics Holdings (Pernix) (NASDAQ: PTX) is a publicly traded specialty pharmaceutical company primarily focused on the sales, marketing, and development of branded pharmaceutical products. The Company markets a portfolio of branded products, including: TREXIMET®, SILENOR®, a non-narcotic product indicated for the treatment of insomnia characterized by difficulties with sleep maintenance, KHEDEZLA™, as well as CEDAX®, an antibiotic for middle ear infections. The Company promotes its branded products to physicians through its Pernix sales force and distributes its generic portfolio through its wholly owned subsidiaries, Cypress Pharmaceuticals and Macoven Pharmaceuticals. Founded in 1996, the Company is based in Morristown, New Jersey. In 2014, Pernix became one of the fastest growing specialty pharmaceutical companies in the US, with an expanding CNS franchise and opportunities to branch out into adjacent therapeutic areas. Additionally, in 2014, the company completed several acquisitions including the acquisition of TREXIMET® from GSK and KHEDEZLA™ from Osmotica. In 2013, the company completed several acquisitions of pharmaceutical companies including Cypress Pharmaceuticals, Inc., Hawthorn Pharmaceuticals, Inc., Somaxon Pharmaceuticals Inc.